Novanta Inc
$ 166.37
1.87%
07 Aug - close price
- Market Cap 5,816,365,000 USD
- Current Price $ 166.37
- High / Low $ 170.39 / 164.03
- Stock P/E 109.61
- Book Value 36.81
- EPS 1.49
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.05 %
- 52 Week High 176.38
- 52 Week Low 98.27
About
Novanta Inc. designs, manufactures, markets and sells precision motion, vision and photonics components and subsystems to original equipment manufacturers in the medical and industrial markets worldwide. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$175.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-11 | 2026-02-23 | 2025-11-03 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-28 | 2023-11-07 |
| Reported EPS | 0.89 | 0.81 | 0.91 | 0.87 | 0.76 | 0.74 | 0.76 | 0.85 | 0.73 | 0.74 | 0.63 | 0.85 |
| Estimated EPS | 0.83 | 0.78 | 0.88 | 0.82 | 0.73 | 0.67 | 0.7133 | 0.85 | 0.69 | 0.58 | 0.63 | 0.74 |
| Surprise | 0.06 | 0.03 | 0.03 | 0.05 | 0.03 | 0.07 | 0.0467 | 0 | 0.04 | 0.16 | 0 | 0.11 |
| Surprise Percentage | 7.2289% | 3.8462% | 3.4091% | 6.0976% | 4.1096% | 10.4478% | 6.547% | 0% | 5.7971% | 27.5862% | 0% | 14.8649% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NOVT
2026-08-06 23:10:23
Novanta (NOVT) reported a strong second quarter of 2026, with GAAP revenue up 10% to $266 million and organic growth of 9.3%. The company saw significant profitability improvements, including a 16% increase in adjusted EBITDA to $60.7 million and a 17% rise in adjusted diluted EPS to $0.89. Analysts currently rate NOVT with a Buy, while TipRanks' AI Analyst, Spark, has a Neutral rating, noting strong fundamentals but expensive valuation and weaker near-term technicals.
2026-08-06 13:43:30
Novanta Inc. (NOVT) has reached a new 52-week high of $172.31, reflecting a 34.62% return over the past year and a 28.68% gain year-to-date. Despite its strong performance, InvestingPro analysis indicates the stock is currently overvalued with a P/E ratio of 109.36 and a market cap of $6.31 billion. The company recently surpassed Q2 2026 earnings and revenue expectations, raising its outlook.
2026-08-06 00:43:31
Novanta Inc (NOVT) reported strong Q2 2026 financial results with GAAP revenue up 10.3% to $265.8 million and GAAP diluted EPS of $0.30, driven by operational execution and acquisitions. Despite a slight overvaluation according to GuruFocus' GF Value, the company shows robust financial strength and profitability. However, recent insider stock sales suggest potential caution for investors.
2026-08-05 22:43:31
Novanta (Nasdaq: NOVT) reported strong Q2 2026 results with a 10.3% year-over-year revenue increase to $265.8 million and 9.3% organic growth, the highest since Q1 2023. GAAP diluted EPS rose significantly to $0.30, and adjusted EBITDA grew 16.4% to $60.7 million, with company-wide gross and adjusted EBITDA margins expanding. The company's Q3 and full-year guidance includes the Riverpoint Medical acquisition, which is expected to be immediately accretive and increase medical end-market exposure.
2026-08-05 21:11:27
Novanta Inc. (NOVT) reported Q2 adjusted EPS of $0.89 per share, surpassing FactSet's estimate of $0.83. This news comes as the company also announced rising Q2 adjusted earnings and revenue, leading to a lift in its 2026 guidance. Novanta also provided Q3 revenue and adjusted EPS guidance, along with news of its recent acquisition of Riverpoint Medical, LLC.
2026-08-05 18:43:31
Novanta Inc. reported strong financial results for the second quarter of 2026, with GAAP revenue increasing 10% to $266 million and Adjusted EBITDA up 16% to $61 million. The company exceeded expectations in revenue, margins, and profitability, and also announced the acquisition of Riverpoint Medical, which is expected to significantly boost its medical consumables business and overall financial performance. Novanta provided optimistic financial guidance for the third quarter and full year 2026, incorporating the contributions from the recent acquisition.
